Earnings call transcript: Equifax beats Q1 2026 earnings expectations

Equifax reported Q1 2026 EPS of $1.86 versus $1.70 expected and revenue of $1.649 billion versus $1.62 billion expected, with revenue up 14% year over year and EBITDA up 13% to $477 million. Strength was led by a 38% jump in U.S. mortgage revenue and continued gains from cloud and AI initiatives, but shares fell 2.66% pre-market as management kept full-year guidance unchanged amid Iran-related macro and rate uncertainty. The company also reiterated over $1 billion of free cash flow for 2026 and continued capital returns via dividends and buybacks.

Analysis

EFX is turning its data moat into a monetization moat: the market is still treating the stock like a cyclical credit proxy, but the mix is shifting toward higher-quality, software-like revenue streams with operating leverage from cloud and AI. The underappreciated second-order effect is that “free” front-end data products are a customer-acquisition cost, not a giveaway; if they lift share in mortgage, auto, and personal loans, Equifax can expand its installed base before any score-pricing regime changes, creating a longer-duration annuity on downstream verification and analytics.

The near-term debate is not earnings quality but duration of mortgage strength. The stock is being penalized because investors are discounting a lower-rate backdrop and headline geopolitics, yet the larger setup is a refi option chain: a large cohort of borrowers sits above today’s rate levels, so even modest easing can re-accelerate inquiries and amplify leverage in the revenue model. That means the risk is less a collapse in demand than a timing mismatch—EFX may look too conservative for one or two quarters and then mechanically re-rate when rates normalize.

The biggest contrarian miss is that VantageScore is not just a long-dated upside option; it is also a strategic bargaining chip that can accelerate customer lock-in across mortgage and non-mortgage channels. Even if agency adoption slips, the company is already training lenders to dual-source and embedding itself deeper into workflow, which should widen switching costs and preserve share. The main downside tail risk is government timing: if Medicaid/SNAP implementation drags into 2027, investors may over-penalize the stock despite the fact that the pipeline is becoming more valuable, not less, because adoption tends to arrive in bursts once procurement clears.

Key Decisions for Investors

• Go long EFX on weakness over the next 1-2 sessions; use the pre-market selloff as entry for a 3-6 month trade targeting a re-rating once the market refocuses on FCF conversion and buybacks. Risk/reward: ~10-15% upside to a modest multiple re-rate, with low fundamental downside absent a sharp mortgage collapse.
• Pair trade: long EFX / short FICO for a 3-9 month horizon. EFX has the cleaner torque to a VantageScore adoption surprise while FICO carries more regulatory/pricing overhang; the asymmetry improves if agency activation gets closer without immediate full conversion.
• Buy EFX Jan-2027 call spreads on a pullback to capture the optionality from VantageScore adoption and mortgage normalization. Structure for moderate premium outlay; thesis breaks only if rates stay elevated and adoption stalls into 2027.
• Keep an eye on CMS-adjacent names and government verification proxies, but avoid chasing them here; the revenue inflection is likely 2027+, so the near-term set-up is better expressed through EFX rather than a pure government-beta trade.
• If mortgage rates fall materially over the next 1-2 quarters, add to EFX rather than fade it; the operating leverage on both revenue and margin is likely underappreciated, and the market will likely be forced to revise 2026 guidance upward.